HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival
7 Dec 2017
HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival
Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer
Increasing the dose intensity of chemotherapy may lower the risk of breast cancer recurrence and death
The importance of data connectivity and e-health
A world wide web for genomic data
The reality of pancreatic cancer
Personalised medicine for inherited breast cancer
Precision Panc, a platform for pancreatic cancer
Lung cancer screening across Europe
A biological perspective for personalising immunotherapies
Multi gene panels for cancer prevention in Italy
Creating likely scenarios for healthcare